VelosBio has filed 7 patents.
Clusters of differentiation, Transcription factors, Monoclonal antibodies, Experimental cancer drugs, Immunology
Clusters of differentiation, Transcription factors, Monoclonal antibodies, Experimental cancer drugs, Immunology
Latest VelosBio News
Sep 13, 2023
| Key Companies in the Market - Beam, Pfizer, Genentech, AbbVie, Fate, Roche, Ascentage, Janssen, Jazz, ADC, Kymera, Syndax, ImmunoGen News provided by Share this article Share toX The dynamics of the acute lymphocytic leukemia market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies. LAS VEGAS, Sept. 13, 2023 /PRNewswire/ -- DelveInsight's Acute Lymphocytic Leukemia Market Insights report includes a comprehensive understanding of current treatment practices, acute lymphocytic leukemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Key Takeaways from the Acute Lymphocytic Leukemia Market Report As per DelveInsight analysis, the acute lymphocytic leukemia market is expected to grow positively at a significant CAGR during the study period (2019–2032). As per the American Cancer Society's estimations, there are approximately 6,540 new acute lymphocytic leukemia cases in the United States for 2023 (covering both children and adults). Leading acute lymphocytic leukemia companies such as Beam Therapeutics Inc., Pfizer, Genentech, Inc., Jazz Pharmaceuticals, PeproMene Bio, Inc., Kymera Therapeutics, Inc., Amgen, ADC Therapeutics S.A., Bayer, Meryx, Inc., Chimagen Biosciences, Ltd, SecuraBio, Sanofi, Autolus Limited, Wugen, Inc., Precision BioSciences, Inc., Oncoceutics, Inc., Servier, Biomea Fusion Inc., Syndax Pharmaceuticals, Ascentage Pharma Group Inc., Janssen Research & Development, LLC, AbbVie, Fate Therapeutics, Hoffmann-La Roche, Orca Biosystems, Inc., Bellicum Pharmaceuticals, Sun Pharma Advanced Research Company Limited, Newave Pharmaceutical Inc, Athenex, Inc., VelosBio Inc., Nkarta Inc., Sumitomo Pharma Oncology, Inc., Actuate Therapeutics Inc., ImmunoGen, Inc, AVM Biotechnology Inc, Medpace, Inc., Lava Therapeutics, and others are developing novel acute lymphocytic leukemia drugs that can be available in the acute lymphocytic leukemia market in the coming years. Some key therapies for acute lymphocytic leukemia treatment include BEAM-201, Inotuzumab ozogamicin, Venetoclax, CPX-351, BAFFR-CAR T cells, KT-253, Blinatumomab, ADCT-602, Copanlisib, MRX-2843, 1A46 Injection, Duvelisib, SAR443579, AUTO1, WU-CART-007, PBCAR0191, Akt/ERK Inhibitor ONC201, Calaspargase pegol (S95015), BMF-500, and others. Discover which therapies are expected to grab the major acute lymphocytic leukemia market share @ Acute Lymphocytic Leukemia Market Report Acute Lymphocytic Leukemia Overview Acute lymphocytic leukemia, also known as acute lymphoblastic leukemia, is a type of blood cancer that primarily affects the lymphocytes, a type of white blood cell. This disease is characterized by the rapid production of immature lymphocytes in the bone marrow, which interferes with the production of healthy blood cells. The exact acute lymphocytic leukemia causes are not fully understood, but certain genetic and environmental factors are believed to contribute to its development. In some cases, specific genetic mutations can increase the risk of developing acute lymphocytic leukemia. The acute lymphocytic leukemia symptoms can vary but often include fatigue, pale skin, frequent infections, easy bruising or bleeding, bone pain, and swollen lymph nodes. Because the cancerous cells interfere with normal blood cell production, individuals with acute lymphocytic leukemia might experience anemia, increased susceptibility to infections, and bleeding problems. Diagnosing acute lymphocytic leukemia involves a series of tests including blood tests, bone marrow aspiration and biopsy, and imaging studies. Blood tests can reveal abnormal levels of white blood cells and other blood cell types. Bone marrow tests provide insight into the number and appearance of leukemia cells. Additionally, genetic and molecular tests might be conducted to identify specific genetic abnormalities that can help guide treatment decisions. Acute Lymphocytic Leukemia Epidemiology Segmentation The acute lymphocytic leukemia epidemiology section provides insights into the historical and current acute lymphocytic leukemia patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The disease epidemiology covered in the report provides historical as well as forecasted acute lymphocytic leukemia epidemiology scenarios in the 7MM covering the United States, EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan from 2019 to 2032. Acute Lymphocytic Leukemia Treatment Market In recent years, significant advancements in the understanding of the genetic and molecular basis of acute lymphocytic leukemia have led to the development of targeted therapies. These therapies specifically focus on inhibiting the signaling pathways or molecular abnormalities that drive the growth of leukemia cells. These targeted drugs can be used in combination with traditional chemotherapy or as standalone treatments for certain subtypes of acute lymphocytic leukemia. This personalized approach not only increases the effectiveness of treatment but also minimizes the side effects associated with standard chemotherapy. Stem cell transplantation, particularly allogeneic transplantation, plays a critical role in treating high-risk and relapsed cases of acute lymphocytic leukemia. This procedure involves replacing the patient's diseased bone marrow with healthy stem cells from a compatible donor, which can help reestablish a healthy blood cell production environment. Immunotherapy has also emerged as a promising avenue in acute lymphocytic leukemia treatments. Chimeric Antigen Receptor (CAR) T-cell therapy, for example, involves genetically modifying a patient's own T-cells to recognize and attack leukemia cells. This innovative approach has shown remarkable success, particularly in cases that are resistant to other treatments. Despite these advancements, acute lymphocytic leukemia treatment can be intense and challenging, often leading to a range of side effects including nausea, fatigue, increased susceptibility to infections, and in some cases, long-term health issues. Therefore, comprehensive supportive care is an integral part of the treatment plan, aimed at managing these side effects and enhancing the patient's overall well-being. As research continues to uncover new insights into the biology of acute lymphocytic leukemia, the treatment landscape is expected to further evolve, offering even more precise and effective therapeutic options for individuals battling this complex disease. Key Acute Lymphocytic Leukemia Therapies and Companies BEAM-201: Beam Therapeutics Inc. KT-253: Kymera Therapeutics, Inc. Duvelisib: SecuraBio Calaspargase pegol (S95015): Servier BMF-500: Biomea Fusion Inc. Acute Lymphocytic Leukemia Market Dynamics The acute lymphocytic leukemia market is characterized by a complex interplay of drivers and barriers that significantly influence its dynamics. On the driver's side, advances in medical research and technology have led to improved diagnostics, better understanding of disease pathways, and the development of targeted therapies. These innovations have enhanced treatment outcomes, extended patient survival rates, and increased the overall quality of life for acute lymphocytic leukemia patients. Additionally, growing investments in healthcare infrastructure, rising awareness campaigns, and supportive government initiatives have propelled the demand for effective acute lymphocytic leukemia treatments. However, the acute lymphocytic leukemia market also faces substantial barriers. One major challenge is the high cost of novel therapies and treatments, which can limit accessibility for a significant portion of patients, particularly in low-resource regions. Regulatory hurdles and lengthy approval processes for new treatments can hinder the rapid introduction of cutting-edge therapies. Furthermore, the heterogeneity of acute lymphocytic leukemia, where various genetic mutations can lead to different disease manifestations, poses difficulties in finding universally effective treatments. Also, potential side effects and adverse events associated with certain treatments can affect patient adherence and acceptance. In summary, while there are driving forces pushing the acute lymphocytic leukemia market forward, barriers related to cost, regulation, and medical complexities create a dynamic landscape that necessitates ongoing efforts to optimize patient care and treatment accessibility. Report Metrics Key Acute Lymphocytic Leukemia Companies Beam Therapeutics Inc., Pfizer, Genentech, Inc., Jazz Pharmaceuticals, PeproMene Bio, Inc., Kymera Therapeutics, Inc., Amgen, ADC Therapeutics S.A., Bayer, Meryx, Inc., Chimagen Biosciences, Ltd, SecuraBio, Sanofi, Autolus Limited, Wugen, Inc., Precision BioSciences, Inc., Oncoceutics, Inc., Servier, Biomea Fusion Inc., Syndax Pharmaceuticals, Ascentage Pharma Group Inc., Janssen Research & Development, LLC, AbbVie, Fate Therapeutics, Hoffmann-La Roche, Orca Biosystems, Inc., Bellicum Pharmaceuticals, Sun Pharma Advanced Research Company Limited, Newave Pharmaceutical Inc, Athenex, Inc., VelosBio Inc., Nkarta Inc., Sumitomo Pharma Oncology, Inc., Actuate Therapeutics Inc., ImmunoGen, Inc, AVM Biotechnology Inc, Medpace, Inc., Lava Therapeutics, and others Key Acute Lymphocytic Leukemia Therapies BEAM-201, Inotuzumab ozogamicin, Venetoclax, CPX-351, BAFFR-CAR T cells, KT-253, Blinatumomab, ADCT-602, Copanlisib, MRX-2843, 1A46 Injection, Duvelisib, SAR443579, AUTO1, WU-CART-007, PBCAR0191, Akt/ERK Inhibitor ONC201, Calaspargase pegol (S95015), BMF-500, and others Scope of the Acute Lymphocytic Leukemia Market Report Therapeutic Assessment: Acute Lymphocytic Leukemia current marketed and emerging therapies Acute Lymphocytic Leukemia Market Dynamics: Conjoint Analysis of Emerging Acute Lymphocytic Leukemia Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Acute Lymphocytic Leukemia Market Access and Reimbursement Table of Contents Acute Lymphocytic Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute lymphocytic leukemia companies, including PersonGen BioTherapeutics, Takara Bio Inc., Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Orca Biosystems, Inc., Sanofi, Beijing Immunochina Medical Science & Technology Co., Ltd., Actinium Pharmaceuticals, Nanjing Bioheng Biotech Co., Ltd., Legend Biotech, Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Kymera Therapeutics, PeproMene Bio, Inc., Takeda Oncology, OneChain Immunotherapeutics, JW Therapeutics, Jazz Pharmaceuticals, Novartis, BRL Medicine, Meryx, Inc., Syndax Pharmaceuticals, Janssen Research & Development, LLC, Daiichi Sankyo Company, SecuraBio, Fate Therapeutics, In8bio Inc., Newave Pharmaceutical Inc, AstraZeneca, Biomea Fusion Inc., Karyopharm Therapeutics Inc, Nkarta Inc., Athenex, Inc., ERYtech Pharma, Chongqing Precision Biotech Co., Ltd, Incyte Corporation, BioLineRx, Ltd, OSE Immunotherapeutics, Aleta Biotherapeutics, CalciMedica, Inc., Cabaletta Bio, Hebei Senlang Biotechnology, among others.
VelosBio Frequently Asked Questions (FAQ)
When was VelosBio founded?
VelosBio was founded in 2017.
Where is VelosBio's headquarters?
VelosBio's headquarters is located at 11045 Roselle Street, San Diego.
What is VelosBio's latest funding round?
VelosBio's latest funding round is Acquired.
How much did VelosBio raise?
VelosBio raised a total of $201.48M.
Who are the investors of VelosBio?
Investors of VelosBio include Merck & Co., Decheng Capital, Takeda Ventures, Pappas Ventures, Arix Bioscience and 20 more.